ViaDerma, Inc. manufactures and sells pharmaceutical related products. The company is headquartered in Las Vegas, Nevada. The company went IPO on 2008-06-10. The firm is engaged in the manufacture and sale of pharmaceutical related products in the United States of America. The Company’s lead product is a topical antibiotic, which is focused on being sold under the brand name Vitastem. The firm also has products in development in the fields: anti-aging skin care, pain management, hair-loss, and toenail fungus. Its products are based on a patent-pending delivery system technology that allows for rapid mass transfer of the pharmaceutical active ingredient across the skin and into the body to provide immediate localized therapy. The firm utilizes a specific trade secret formulation system in the manufacture of all products. The Company’s products are sold to local medical practitioners and patients in clinics primarily in the Los Angeles, California area. The Company’s subsidiary is ViaDerma, II Inc.
How did VDRM's recent EPS compare to expectations?
The most recent EPS for Viaderma Inc is $, expectations of $.
How did Viaderma Inc VDRM's revenue perform in the last quarter?
Viaderma Inc revenue for the last quarter is $
What is the revenue estimate for Viaderma Inc?
According to of Wall street analyst, the revenue estimate of Viaderma Inc range from $ to $
What's the earning quality score for Viaderma Inc?
Viaderma Inc has a earning quality score of A-/61.569263. The score is based on a four dimension of Profitability, Growth, Cash generation & Capital Allocation, and Leverage.
When does Viaderma Inc report earnings?
Viaderma Inc next earnings report is expected in 2026-03-23
What are Viaderma Inc's expected earnings?
Viaderma Inc expected earnings is $, according to wall-street analysts.